Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by equities researchers at Canaccord Genuity in a report issued on Monday.

The analysts wrote, “Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.””

Other equities research analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $540.00 price objective (up previously from $480.00) on shares of Regeneron Pharmaceuticals in a report on Friday, June 30th. BidaskClub downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Bank of America Corp reissued a “buy” rating and issued a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Citigroup Inc. increased their price objective on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a report on Friday, August 4th. Finally, UBS AG reissued a “buy” rating and issued a $535.00 price objective (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus price target of $489.92.

Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.61% during mid-day trading on Monday, reaching $445.68. 508,714 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $456.72 and a 200 day moving average price of $455.81. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The company has a market cap of $47.26 billion, a PE ratio of 44.71 and a beta of 1.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.82 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post $14.94 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Reaffirms “Buy” Rating for Regeneron Pharmaceuticals, Inc. (REGN)” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/16/canaccord-genuity-reaffirms-buy-rating-for-regeneron-pharmaceuticals-inc-regn.html.

In related news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sanofi acquired 166,415 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold 89,468 shares of company stock worth $42,312,448 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. Oppenheimer & Co. Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 20.6% during the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after purchasing an additional 1,199 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $220,000. Blair William & Co. IL boosted its stake in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares in the last quarter. Finally, National Pension Service boosted its stake in shares of Regeneron Pharmaceuticals by 10.8% during the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after purchasing an additional 6,481 shares in the last quarter. 67.40% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.